Bristol-Myers Squibb Company
Bristol-Myers Squibb Announces Completion of €4.9 Billion Notes Offering
Summary
On November 10, 2025, Bristol-Myers Squibb's subsidiary, BMS Ireland Capital Funding Designated Activity Company, completed a public offering of €4.9 billion aggregate principal amount of various notes due between 2030 and 2055. The notes, fully guaranteed by Bristol-Myers Squibb, bear interest rates ranging from 2.973% to 4.581% per annum and are governed by an Indenture dated October 31, 2025, and supplemented by a First Supplemental Indenture dated November 10, 2025. The net proceeds from the offering will be used to fund a tender offer for the company's outstanding notes, pay related fees and expenses, and for general corporate purposes.
Profitelligence Alerts
Get alerts for BMY
Be first to know when Bristol-Myers Squibb Company files with the SEC.
Filing Categories
Advertisement
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is a renowned pharmaceutical corporation engaged in the discovery, development, and distribution of innovative medicines. The company's core focus lies in providing therapeutic solutions for areas such as oncology, immunology, cardiovascular disease, and fibrotic diseases. Founded in 1887 and headquartered in New York City, it has grown into a key player in the global healthcare market, influencing medical advancements and treatment protocols. Bristol-Myers Squibb is pivotal for its groundbreaking contributions to cancer treatment, particularly through its development of immunotherapy drugs, which alter and assist the immune system's ability to fight cancer cells. Additionally, the firm extends its impacts across multiple sectors, affecting industries such as biotechnology, pharmaceuticals, and healthcare. The company's significance is underscored by its extensive research and development investments, often collaborating with research institutions and academic entities worldwide to pioneer new treatments. Such collaborations expand its influence beyond product distribution to shaping future healthcare landscapes. Bristol-Myers Squibb's commitment to innovation and addressing unmet medical needs makes it a prominent entity in the pharmaceutical sector.
Official SEC Documents
Advertisement